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Natural and synthetic estrogens, including diethylstilbestrol (DES), given during the critical period 
of newborn life induce abnormalities in ovaries of mice. Induction of polyovular follicles (PFs) con-
taining two or more oocytes in a follicle is one example. In this study, the involvement of estrogen 
receptor subtypes ERα and ERβ in induction of PFs by neonatal treatment with DES was analyzed 
by using ERα knockout (αERKO) and ERβ knockout (βERKO) mice. Ovaries of mice injected with 
3 μg DES for 5 days from the day of birth were examined histologically from 10 to 60 days of age, 
and the expression of genes involved in folliculogenesis was analyzed by real-time quantitative 
PCR. The PF incidence (percent of PFs per 100 follicles greater than 50 μm in diameter) in the ovary 
of αERKO mice treated with DES was not different from that in the DES-treated wild-type mice. 
However, neonatal DES treatment did not increase the PF incidence in βERKO mice, suggesting 
that PFs were induced by DES through ERβ but not ERα. The expression of bone morphogenetic 
protein 15, growth differentiation factor 9, inhibin-α, Müllerian inhibiting substance, and other genes 
in the ovaries of DES-treated βERKO mice was not different from that in the ovaries of DES-treated 
wild-type mice. These results indicate that ERβ but not ERα is essential for DES to induce PFs in 
mice.
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INTRODUCTION
Newborn female mice have been used as a rodent 
model to understand the mechanisms of estrogen action 
responsible for the human diethylstilbestrol (DES) syndrome 
in which pregnant women during the period from the 1940s 
to 1970s were prescribed DES to prevent miscarriage. 
Daughters born from these DES-exposed mothers devel-
oped vaginal cancer and other reproductive abnormalities 
(Herbst and Bern, 1981). DES use in women was stopped 
in 1971. Neonatal DES treatment induces various abnormal-
ities in female mouse reproductive organs, including persis-
tent cornification of the vaginal epithelium (Takasugi, 1963, 
1976) and tumorigenesis in the mammary gland (Lopez et 
al., 1988). Neonatal treatment of mice with DES induces 
several histological abnormalities in the ovary, including 
polyovular follicles (PFs) having two or more oocytes in a 
follicle, ovarian cysts, hemorrhagic cysts, hypertrophy of the 
interstitial tissue, and the absence of corpora lutea. The lack 
of corpora lutea in the ovaries of neonatally DES-treated 
mice was caused by lack of a surge of luteinizing hormone 
(Hayashi and Aihara, 1989; Hayashi et al., 1991; Döhler and 
Jarzab, 1992).
Estrogen acts through binding to two cognate nuclear 
receptors, estrogen receptor (ER) α and ERβ, in female 
reproductive organs. DES binds to both ERα and ERβ with 
high affinity compared to 17β-estradiol (E2) (Kuiper et al., 
1997). The uterus, mammary gland, placenta, liver, central 
nervous system, cardiovascular system, and bone have high 
ERα content. ERβ is detected in the prostate, testis, ovary, 
pineal gland, thyroid gland, and skin, and is especially highly 
expressed in the prostatic epithelium, urogenital tract, 
ovarian follicles, lung, and muscle (Weihua et al., 2003). In 
mouse ovaries, ERα mRNA and protein are localized in 
interstitial and thecal cells, and ERβ expression is detected 
in the nuclei of granulosa cells (Jefferson et al., 2002; 
Hishikawa et al., 2003). In studies with ERα knockout 
(αERKO) and ERβ knockout (βERKO) mice, and the use of 
ER selective ligands, DES was shown to act through ERα
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but not ERβ in the induction of squamous epithelial meta-
plasia in the uterus, proliferative lesions of the oviduct, 
persistent cornification of the vaginal epithelium, and hyper-
trophy of the ovarian interstitial tissue (Couse and Korach, 
2004; Nakamura et al., 2008).
PFs are found in the ovary of intact mice, rats, hamsters, 
dogs, and other species of mammals, including humans 
(Iguchi, 1992; Iguchi and Sato, 2000). The PF incidence is 
different among strains in intact mice (Kent, 1960), and it is 
increased markedly by neonatal DES treatment (Forsberg, 
1985; Iguchi, 1985; Iguchi et al., 1987). In C57BL/Tw mice, 
PFs are induced with high incidence by neonatal treatment 
with estrogens, progestins, and aromatizable androgen, tes-
tosterone (T), but not by the non-aromatizable androgens 
5α-dihydrotestosterone (5α-DHT) or 5β-DHT (Iguchi et al., 
1986). In addition, simultaneous administration of aromatase 
inhibitor (4-hydroxy-4-androstene-3, 17-dion) and T does not 
induce PFs (Iguchi et al., 1988). The evidence suggests that 
T enhances PF induction as a result of its conversion to 
estrogen (Ryan et al., 1972). DES acts directly on the neo-
natal ovary to induce PFs both in vivo and in vitro (Iguchi et 
al., 1990); however, it has been unclear which ER subtype is 
involved in the PF induction by neonatal DES treatment.
Even without DES treatment, PFs are found in the 
ovaries of double mutant bone morphogenetic protein 15 
(Bmp-15)–/– and growth differentiation factor 9 (Gdf-9)+/– 
mice (Yan et al., 2001). Mice overexpressing inhibin-α gene 
also show a high incidence of PFs (McMulle et al., 2001). 
Thus, the induction of PFs by DES may be accompanied by 
changes in BMP-15 and/or inhibin-α expression. In addition, 
studies of Müllerian inhibiting substance (MIS) and steroido-
genic factor-1 (SF-1) deficient mice suggest that both are 
critical factors in regulating early ovarian differentiation 
(Durlinger et al., 1999).
In the present study, DES-treated αERKO and βERKO 
mice were used to examine whether DES acts through ERα
and/or ERβ in neonatal mouse ovaries to induce PFs and 
histological abnormalities. Using real-time quantitative PCR, 
changes in the expression of several genes reported to be 
involved in folliculogenesis and in PF occurrence were com-
pared between DES-treated and oil-treated mouse ovaries.
MATERIALS AND METHODS
Animals
As the developmental stage of the reproductive tract of mouse 
neonates corresponds to that of the 3- to 4-month-old human fetus, 
the neonatal mouse has been used as an animal model of human 
DES syndrome, in which DES was prescribed during 3–5 months 
of pregnancy to prevent abortion (Bern and Talamantes, 1981). 
Therefore, we used neonatal mice for this study.
Female C57BL/6J Jcl mice (CLEA Japan, Tokyo); αERKO 
(ERα–/–), wild-type (ERα+/+), and heterozygous (ERα+/–) females; 
and βERKO (ERβ–/–), wild-type (ERβ+/+), and heterozygous 
(ERβ+/–) females were given daily subcutaneous (s.c.) injections of 
3 μg diethylstilbestrol (DES) (Sigma Chemical, St. Louis, MO, USA) 
dissolved in sesame oil or in the vehicle alone for 5 days, starting 
on the day of birth (day 0).
αERKO and βERKO mice were obtained by mating mice of a 
mixed C57BL6/129sv background that were heterozygous for the 
ER gene disruption, as described previously (Dupont et al., 2000). 
Pup genotypes were determined by multiplex PCR.
All animals were fed a commercial diet (MF, Oriental Yeast, 
Tokyo) and tap water ad libitum and kept at 24±1.0°C under 12 h 
light/12 h darkness (artificial illumination; lights on 0800–2000). Ani-
mals were maintained in accordance with the NIH Guide for the 
Care and Use of Laboratory Animals, and the procedures were 
approved by our institutional animal care committee.
Histological analysis
Ovaries of C57BL/6J mice at days 5, 10, 20, 30, 40, 50, and 
60 (n=5), αERKO and βERKO mice at day 30 (n=7–10), and the 
respective wild-type and heterozygous mice (n=4–10) treated neo-
natally with DES or oil vehicle only were fixed in Bouin’s solution 
overnight at room temperature, embedded in paraffin, and serially 
sectioned at 8 μm. Sections were stained with haematoxylin and 
eosin. Every 13th section of ovaries was observed, and the inci-
dence of PFs (%) was estimated by counting the number of PFs 
having more than two oocytes per follicle greater than 50 μm in 
diameter per mouse, as described previously (Iguchi et al., 1986). 
The number of mice with PFs in C57BL/6J, αERKO, or βERKO 
mice treated neonatally with DES or the oil vehicle was expressed 
as the frequency of PFs.
Immunohistochemistry of ERβ
Ovaries of C57BL/6J mice at days 0, 5, 10, and 20 (n=3) were 
fixed in 4% paraformaldehyde in PBS (pH 7.4) overnight at 4°C, 
embedded in paraffin, and sectioned at 4 μm. Sections were depar-
affinized, rehydrated, and microwaved for 8 min in 10 mM sodium 
citrate buffer (pH 6.0) for antigen retrieval. Sections were incubated 
with 0.3% H2O2 for 10 min to eliminate endogenous peroxidase. 
After washing with PBS, sections were treated with normal goat 
serum for 30 min, and then incubated overnight at 4°C with rabbit 
polyclonal antibody against mouse ERβ (Zymed Laboratories, 
South San Francisco, CA, USA) at a dilution of 1:250, or with the 
rabbit IgG fraction (Dako Cytomation, Glostrup, Denmark) as a neg-
ative control. After incubation with secondary antibody streptavidin 
conjugated to horseradish peroxidase, the Elite Standard ABC Kit 
(Vector Laboratories, Burlingame, CA, USA) and 1 mg/ml diamin-
obenzidine (Sigma Chemical) in PBS containing 1% H2O2 were 
used for ERβ detection.
Real-time quantitative PCR
Total RNA was isolated from ovaries of neonatally DES-treated 
or oil-treated C57BL/6J mice at days 5, 10, 20, 30, 40, 50, and 60, and 
neonatally DES-treated or oil-treated wild-type (ERβ+/+) and βERKO 
(ERβ–/–) mice at days 10, 20, and 30, and reverse-transcribed with 
Super Script II reverse transcriptase (Invitrogen, Carlsbad, CA, 
USA) using 0.05 mM oligo dT primer (Invitrogen). Real-time quan-
titative PCR was carried out with an ABI PRISM 7000 Sequence 
Detection System using SYBR Green Master Mix (Applied Bio-
systems, Foster City, CA, USA). The relative mRNA expression of 
BMP-15, GDF-9, inhibin-α, MIS, kit (KIT), kit ligand (KL), insulin-like 
growth factor I (IGF-I), SF-1, steroidogenic acute regulatory protein 
(StAR), cholesterol side-chain cleavage cytochrome P450 
(P450SCC), ERα, and ERβ (Table 1) was determined by the stan-
dard curve method. Cyclophilin was chosen as an internal standard 
to control for variability in amplification due to differences in starting 
mRNA concentration. One to ten mice were used for each time 
point. Independent experiments were carried out at least three 
times for each gene.
Statistical analysis
Data are expressed as the mean±standard error. For multiple 
comparisons, treatment groups were compared using analysis of 
variance (ANOVA) followed by Dunnett’s post-hoc test. Two-tailed 
Student’s t-tests were used for single comparisons. Fisher’s exact 
probability test was used to examine the significance of the associ-
ation between the two kinds of classification. A statistically signifi-
cant difference was defined as p<0.05.
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RESULTS
Polyovular follicles (PFs) in the 
ovary of DES-treated C57BL/6J 
mice
The histology of ovaries from 
5- and 10-day-old mice showing 
ovarian follicles in a variety of 
stages was not altered by neona-
tal DES treatment. Corpora lutea 
were found in the ovaries of 
C57BL/6J control mice at day 40 
or older, but not in the ovaries of 
any DES-treated mice (data not 
shown). This result corresponds 
with a previous report (Iguchi, 
1992).
PFs greater than 50 μm in diameter were found in the 
ovaries of all DES-treated C57BL mice at day 10 or older. 
In control mice, 20 –100% of mice had PFs in the ovary from 
days 10 to 60; therefore, DES treatment did not significantly 
increase the PF frequency (percent of mice with PFs), 
except in 60-day-old mice (Table 2). The number of follicles 
greater than 50 μm in diameter was significantly higher in 
the ovaries of 20- to 60-day-old mice than in those of 10-day-
old mice in both the oil- and DES-treated groups. In 30- and 
50-day-old DES-treated mice, the total number of follicles 
was larger compared to the age-matched oil controls (Fig. 
1A). The PF incidence (percent of PFs per 100 follicles 
greater than 50 μm in diameter) was significantly higher in 
DES-treated mice from days 20 to 60 than in the age-
matched controls. The PF incidence was highest (15.7± 
2.02%) in neonatally DES-treated mice at day 20 and 
decreased gradually with age (Fig. 1B). The total number of 
PFs per ovary in DES-treated mice increased to day 30 and 
then decreased with age. PFs with two or three oocytes 
were significantly higher at days 20 to 40 (Fig. 1C).
Expression of genes involved in folliculogenesis in 
C57BL/6J mice
To analyze the mRNA expression of folliculogenesis-
related genes, including BMP-15, GDF-9, inhibin-α, MIS, Kit, 
KL, and IGF-I, real-time quantitative PCR was performed. In 
Table 2.?Number and frequency of mice with PFs among C57BL/         
6J mice treated neonatally with the oil vehicle or with 3 μg DES.
Treatments
Days of age
10 20 30 40 50 60
Oil
No. of mice
with PFs / No.
of mice examined
2 / 5 5 / 5 2 / 5 4 / 6 2 / 5 1 / 5
PFs frequency (%) 40 100 40 67 40 20
DES
No. of mice
with PFs / No.
of mice examined
5 / 5 5 / 5 5 / 5 5 / 5 5 / 5 5 / 5*
PFs frequency (%) 100 100 100 100 100 100
*, significantly different (p<0.05) from oil-treated 60-day-old mice 
(Fisher’s exact probability test).
Table 1. Sequences of the oligonucleotide primers used for RT-PCR and real-time quantitative PCR.
Gene Forward sequence (5’ → 3’) Reverse sequence (5’ → 3’)
BMP-15 TCCTTGCTGACGACCCTACATT GGTCAGCCGAACGATGGTATAA
GDF-9 TGGTGGACCTGCTGTTTAACCT CCAGAAGACATGGCCTCCTTTA
Inhibin-α CTGCTCTCAATATCTCCTTCCAAGAG CCATGGCAGTAGTGGAAGATGATGAA
MIS CCTACATCTGGCTGAAGTGATATGG GAGGCTCTTGGAACTTCAGCAA
Kit TACACGTGCAGCAACAGCAA GAAGGCCAACCAGGAAAAGTT
KL GGAAAATAGTGGATGACCACGTGT TGGCCTCTTCGGAGATTCTTT
IGF-I CAGGCATTGTGGATGAGTGTTG CACAGTACATCTCCAGTCTCCTCAGA
P450SCC GTGAATGACCTGGTGCTTCGT TCGACCCATGGCAAAGCTA
SF-1 TTGCCTCCTGAAAGCCACTCT CGCGAAAGCAGGAAAGACA
StAR GCTGCCGAAGACAATCATCA GATGGACAGACTTGCAGGCTT
ERα CCTAGCTCAGCTCCTTCTCATTCTT GGCACAACGTTCTTGCATTTC
ERβ GGTGATTTCGAAGAGTGGAATCTC CCATGCCCTTGTTACTGATGTG
cyclophilin AGGTCCTGGCATCTTGTCCAT CCATCCAGCCATTCAGTCTTG
Fig. 1. (A) Number of follicles and (B) incidence of polyovular folli-
cles (PFs) in ovaries of C57BL/6J mice treated neonatally with oil or 
with 3 μg DES. (C) Number of total PFs and PFs with 2, 3, 4 to 5, or 
6 to 10 oocytes per follicle in ovaries of C57BL/6J mice treated neo-
natally with oil or with 3 μg DES. Data are expressed as the 
mean±standard error. a, significantly different (p<0.05) from age-
matched oil-treated controls (Student’s t-test); b, c, d, significantly 
different (p<0.05) from 10-day-old mice treated neonatally with DES 
(Dunnett’s test). Five mice were used for each time point.
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the ovaries of control mice, the expression of BMP-15, GDF-
9, MIS, and IGF-I showed a peak at day 10. The expression 
of Kit and KL decreased with age. Inhibin-α expression grad-
ually increased to day 20 and remained at a plateau until day 
50. Neonatal DES treatment did not affect the expression of 
any of the genes studied from days 5 to 60, except for 
inhibin-α, which showed a significantly higher level in DES-
treated ovaries than in controls at day 60 (Fig. 2).
Expression of ERα and ERβ mRNA and ERβ protein in 
ovaries of C57BL/6J mice treated neonatally with DES
In oil controls, ERα expression showed no alteration 
from day 0 to day 60. In contrast, ERβ mRNA was signifi-
cantly higher at days 20 and 30 compared to day 0 (Fig. 3). 
Neither the ERα nor the ERβ mRNA level was altered by 
neonatal DES treatment (Fig. 3), even though control mice 
from days 40 to 60 had corpora lutea.
No distinct difference in ERβ immunoreactivity was dis-
cernible between PFs and normal follicles (Fig. 4A). ERβ
was detected distinctly in the nuclei of granulosa cells. No         
ERβ staining was observed in the ovaries of mice at day 0; 
however, granulosa cells began to express ERβ protein from 
day 5 and showed positive immunohistochemical staining 
through day 20 (Fig. 4C, E). ERβ showed no difference in 
immunoreactivity between the ovaries from DES-treated 
mice and those from oil controls (Fig. 4C –F).
Histological analysis of ovaries from αERKO and βERKO 
mice at day 30
Ovaries of oil-injected wild-type mice (ERα+/+ and 
ERβ+/+) at day 30 showed various stages of follicles (Fig. 
5A). PFs were encountered in the age-matched wild-type 
mice treated neonatally with DES (Fig. 5B). Hemorrhagic 
cysts and follicular cysts were found in the ovaries of both 
oil-treated and DES-treated αERKO (ERα–/–) mice (Fig. 5C, 
D). In DES-treated αERKO mice, PFs were induced as in 
the DES-treated wild-type mice (Fig. 5D). Unlike αERKO 
mice, the ovaries of βERKO (ERβ–/–) mice treated with oil 
or DES showed normal follicles at all stages of develop-
ment, without hemorrhagic cysts or follicular cysts (Fig. 5E, 
F). Neonatal DES treatment in βERKO mice (Fig. 6B) did not 
increase the PF incidence. The ovaries of heterozygotes 
(ERα+/– and ERβ+/– mice) were not histologically different 
from those of wild-type mice, and the effects of DES on the 
ovary of these heterozygous mice were similar to those in 
wild-type mice having PFs (data not shown).
PFs in DES-treated αERKO and βERKO mice
The number of follicles in ovaries of αERKO (ERα–/–) 
Fig. 2. Ontogenic expression of genes reported to be involved in 
folliculogenesis in neonatally oil- or DES-treated C57BL/6J mice, 
determined by real-time quantitative PCR. All measurements are 
normalized to the cyclophilin mRNA level and are shown relative to 
the mRNA expresson level at day 0. Data are expressed as the 
mean±standard error. a, significantly different (p<0.05) from age-
matched oil-treated mice (Student’s t-test). One to ten mice were 
used for each time point, and independent experiments were carried 
out at least three times for each gene.
Fig. 3. Ontogenic expression of ERα and ERβ mRNAs in the ova-
ries of oil- or DES-treated C57BL/6J mice, determined by real-time 
quantitative PCR. Cyclophilin was used as an internal standard to 
control for variability in amplification due to differences in starting 
mRNA concentration. Data are expressed as the mean±standard 
error. One to ten mice were used for each time point, and indepen-
dent experiments were carried out at least three times for each 
gene. b, significantly different (p<0.05) from 0-day-old control mice.
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and βERKO (ERβ–/–) mice was not different from respective 
wild-type mice (ERα+/+, ERβ+/+) or heterozygous (ERα+/–, 
ERβ+/–) mice. In ERβ wild-type mice (ERβ+/+), DES treat-
ment significantly increased the number of follicles (Fig. 6A).
Neonatal DES treatment significantly increased the PF 
incidence (percent of PFs per 100 follicles greater than 50 
μm in diameter) in ovaries of ERα wild-type, heterozygous, 
and αERKO mice (Fig. 6B). The PF incidence was not dif-
ferent among DES-treated αERKO mice, ERα heterozygous 
mice, and wild-type mice (9.2 –10.5%). DES-treated ERβ
wild-type and heterozygous mice showed a high incidence 
of PFs; however, DES treatment did not increase the PF 
incidence in βERKO mice compared to that in oil-treated 
βERKO mice (Fig. 6B). In the oil controls, 20 –60% of mice 
had PFs in the ovary at day 30, regardless of genotype, and 
DES treatment did not alter the PF frequency (percent of 
mice with PFs), except in ERβ heterozygous mice (Table 3).
The total number of PFs and the number of PFs with 2, 
3, 4 to 5, or 6 to 10 oocytes were not different among gen-
Fig. 4. Immunohistochemical staining of ERβ protein in ovaries of 
C57BL/6J mice. (A) ERβ positive staining in a PF at day 20. (B–F)
ERβ expression in the ovary of a day 0 mouse (B), day 5 mice 
treated neonatally with oil (C) or with DES (D), and day 10 mice 
treated with oil (E) or with DES (F). (G) Ovary of a day-10 mouse 
incubated with the rabbit IgG fraction as a negative control. The 
cytoplasm of oocytes was occasionally stained, but this was also 
observed in the negative control. Three mice were used for each 
time point. Scale bars, 25 μm.
Fig. 5. Ovarian histology of day-30 wild-type ERα+/+ (A) and 
ERβ+/+ (B) mice, αERKO (ERα–/–) mice (C, D), and βERKO (ERβ–
/–) (E, F) mice treated neonatally with oil (A, C, E) or with 3 μg DES 
(B, D, F). Four to ten mice were used. Scale bar, 100 μm.
Fig. 6. (A) Number of follicles and (B) incidence of PFs in ovaries 
of 30-day-old wild-type (ERα+/+, ERβ+/+), heterozygous (ERα+/–, 
ERβ+/–), αERKO (ERα–/–), and βERKO (ERβ–/–) mice treated 
neonatally with oil or with 3 μg DES. Data are expressed as the 
mean±standard error. a, significantly different (p<0.05) from geno-
type-matched oil-treated mice; b, significantly different (p<0.05) from 
DES-treated heterozygotes and βERKO mice (Student’s t-test).
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otypes in the DES-treated αERKO mouse group (Fig. 7A). 
DES-treated ERβ wild-type (ERβ+/+) mice showed PFs with 
10 oocytes. DES-treated βERKO mice had PFs with two 
oocytes, but the number of PFs was significantly lower than 
in wild-type and heterozygous (ERβ+/–) mice treated neona-
tally with DES (Fig. 7B).
Expression of genes involved in folliculogenesis and 
steroidogenesis in βERKO mice
The expression of BMP-15 showed a peak at day 10 in 
oil-injected wild-type mice and βERKO mice. Neonatal DES 
treatment shifted the peak to day 20 in both wild-type and 
βERKO mice (Fig. 8A). The expression of GDF-9 showed a 
peak at day 10 in wild-type and βERKO mice, irrespective of 
DES treatment. Expression of inhibin-α, SF-1, and P450SCC 
increased with age. Neonatal DES treatment did not affect 
the expression of GDF-9, inhibin-α, MIS, or SF-1 in either 
wild-type or βERKO mice (Fig. 8B–E). The expression of 
StAR peaked at day 20 in wild-type mice but remained low 
in βERKO mice; however, neonatal DES treatment signifi-
cantly increased the expression in βERKO mice at day 30 
(Fig. 8F). In both wild-type and βERKO mice, neonatal DES 
treatment significantly reduced the expression of P450SCC 
at day 10 (Fig. 8G).
DISCUSSION
In mouse ovaries, ERα protein and mRNA are detected 
Table 3. Number and frequency of mice with PFs among different 
phenotypes of 30-day-old mice treated neonatally with DES or with 
the oil vehicle alone.
Treatments Genotypes No. of mice
with PFs
Frequency of mice
with PFs (%)
Oil ERα +/+ 3 / 5  60
ERα +/– 2 / 5  40
ERα –/– 3 / 7  43
ERβ +/+ 3 / 5  60
ERβ +/– 1 / 4  25
ERβ –/– 2 / 10  20
DES ERα +/+ 5 / 5 100
ERα +/– 5 / 5 100
ERα –/– 7 / 7 100
ERβ +/+ 5 / 5 100
ERβ +/– 10 / 10* 100
ERβ –/– 5 / 8  63
*, significantly different (p<0.05) from oil-treated ERβ +/– mice 
(Fisher’s exact probability test).
Fig. 7. (A) Number of total PFs and (B) PFs with 2, 3, 4 to 5, or 6 
to 10 oocytes per follicle in ovaries of 30-day-old wild-type (ERα+/+, 
ERβ+/+), heterozygous (ERα+/–, ERβ+/–), αERKO (ERα–/–), and 
βERKO (ERβ–/–) mice treated neonatally with oil or with 3 μg DES. 
b, c, d, e, f, significantly different (p<0.05) from total PFs, with 2 
oocytes, 3 oocytes, 4–5 oocytes, or 6 –10 oocytes in wild-type 
(ERβ+/+) mice treated with DES, respectively. Four to ten mice were 
used for each time point.
Fig. 8. Ontogenic expression of genes involved in folliculogene-
sis or steroidogenesis in oil- or DES-treated wild-type (ERβ+/+) or 
βERKO (ERβ–/–) mice, determined by real-time quantitative PCR. 
All measurements are normalized to the cyclophilin mRNA level 
and are shown relative to the mRNA expression level of 0-day-old 
mice. Data are expressed as the mean±standard error. a, signifi-
cantly different (p<0.05) from age-matched oil-treated wild-type 
mice (Student’s t-test); b, significantly different (p<0.05) from age-
matched oil-treated βERKO mice (Student’s t-test). One to ten 
mice were used for each time point, and independent experiments 
were carried out at least three times for each gene.
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in the nuclei of interstitial and thecal cells, and ERβ protein 
and mRNA are found in the nuclei of granulosa cells, but not 
in cells in atretic follicles or corpora lutea (Hishikawa et al., 
2003). The localization of ERs suggests that ERβ may play 
a principal role in follicular development, while ERα may be 
involved in LH action and androgen synthesis. Indeed, 
αERKO mouse ovaries exhibit not only hemorrhagic and 
cystic follicles but also growing follicles in the pre-antral to 
small antral stages. The phenotypes of βERKO mouse 
ovaries suggest a reduction in completed folliculogenesis 
(Couse and Korach, 1999). Thus, ERα and ERβ are quite 
distinct in function in the rodent ovary. 
In the present study, neonatal DES treatment increased 
neither the PF frequency nor the PF incidence in βERKO 
mice, whereas DES treatment significantly increased the PF 
incidence in αERKO mice. PFs were also found in C57BL/
6J control mice (20–100%), but the PF incidence was low. 
All DES-treated C57BL/6J mice showed PFs, and the PF 
incidence increased significantly at day 20 and older. 
Nakamura et al. (2008) showed that neonatal treatment with 
a specific ligand of ERα (propyl pyrazole triol) induces PFs 
in C57BL mice, but they also showed in a transactivation 
assay that the ligand could activate ERβ activity at a higher 
concentration. Therefore, the possibility cannot be ruled out 
that the ERα-specific ligand acts through ERβ in the mouse 
ovary. Jefferson et al. (2002) reported the induction of PFs 
by neonatal treatment with 100 μg/pup of genistein, a potent 
phytoestrogen, at day 19, and they found PFs in only one of 
12 βERKO mice. While the binding affinity of genistein to 
ERβ is 20 times higher than that to ERα, DES binds to ERα
and ERβ with equal relative affinity (Kuiper et al., 1998). 
Although the affinities of ERα and ERβ to DES were equal, 
DES treatment did not significantly increase the PF inci-
dence in βERKO mice, but did significantly increased the PF 
incidence in αERKO mice, suggesting that neonatal DES 
treatment induces PFs through ERβ but not ERα. In the 
present study, ERβ protein was not detected at day 0, but it 
was detected by day 5. In addition, neonatal treatment with 
an ERβ-specific agonist, 2,3-bis(4-hydrocyphenyl)-propionitrile 
(25 μg/pup for 5 days from the day of birth, n=5), also 
induced PFs in all wild-type mice at day 30. The PF inci-
dence in oil controls and the ERβ agonist-treated mice was 
0.6 and 4.3%, respectively (unpublished data).
The estrogen-related receptors (ERRs), an orphan 
family of nuclear receptors identified initially by similarity to 
ERα (Giguére et al., 1988), are not activated by natural 
estrogens, but DES can bind and inhibit the transcriptional 
activity of ERRα, β, and γ (Tremblay et al., 2001). While 
ERRα has a potential role in the regulation of metabolic 
homeostasis, loss of ERRβ or ERRγ results in mid-gestational 
or neonatal death due to placental defects or failure of the 
perinatal transition in metabolic state (Luo et al., 1997; 2003; 
Alaynick et al., 2007; Dufour et al., 2007). However, the 
expression of ERRs in the ovaries of neonatal wild-type and 
βERKO mice has not been examined; therefore, the role of 
ERRs in the induction of PFs by DES needs to be clarified 
in the near future.
An increase and decrease of ERβ mRNA with age may 
be correlated with follicle number and follicular development, 
because ERβ is high in preantral and small antral follicles, 
but not in the Graffian follicles or corpora lutea in rats 
(Fitzpatrick et al., 1999). In contrast, ERα is found in the 
interstitial cells of the ovary from the day of birth, and mRNA 
expression is not altered until 26 days of age in mice 
(Jefferson et al., 2000). The ontogeny and distribution of 
ERα and ERβ in the rat ovary are similar to that in the 
mouse ovary (Sar and Welsch, 1999). In addition, no ERβ
staining was observed in the ovaries of mice at day 0; how-
ever, positive immunohistochemical staining of ERβ was 
evident in granulosa cells from days 5 through 20, coinciding 
with the changes in ERβ mRNA expression.
In adult human females, the incidence of PFs ranges 
from 24% to 85%, depending on the study (Gougeon, 1981; 
Dandekar et al., 1988); both reports agree that the propor-
tion of PFs among total follicles in the human ovary is less 
than 1%. No report is available concerning PFs in DES-
exposed humans; however, chronic implants of DES inc-
rease PFs in adult squirrel monkeys (Graham and Bradley, 
1971). In the human ovary, ERβ is localized in the granulosa 
cells of follicles at all stages of development, whereas ERα
is absent from granulosa cells but present in thecal cells 
(Pelletier and El-Alfy, 2000). Thus, it appears that each 
receptor subtype can exert a different function according to 
its specific cellular localization in the human ovary.
In the ovary, ERβ is highly expressed in granulosa cells, 
as discussed above. Our results show clearly that ERβ par-
ticipates in the induction of PFs by neonatal DES exposure. 
ERβ expression is observed in the granulosa cells, but not 
in the oocytes, of rat and human ovaries (Sar and Welsch, 
1999; Jakimiuk et al., 2002; Scobie et al., 2002), while ERβ
mRNA is detected in the cumulus-oocyte complexes and 
denuded oocytes of mice after PMSG and hCG injections 
(Hiroi et al., 1999). Jefferson et al. (2006) demonstrated that 
the suppression of oocyte cell death by neonatal genistein 
treatment results in PFs. Our previous report suggests that 
a delay in or inhibition of oocyte death and an increase in 
inhibin-α by DES through ERβ may be a trigger for PFs for-
mation (Kim et al., in press). Therefore, DES may indirectly 
affect oocyte cell death and induce PFs.
The PF incidence increases only when neonatal DES 
treatment starts within 3 days after birth (Iguchi et al., 1986). 
Exposure to DES from days 15 to 18 of gestation in utero 
also induces a high incidence of PFs in offspring (Iguchi and 
Takasugi, 1986). Folliculogenesis proceeds in ovaries of the 
fetus and neonate. Syncytia, clusters formed by germ cells, 
are invaded by somatic cells and undergo programmed break-
down before the formation of primordial follicles (Epifano and 
Dean, 2002). Thus, DES may induce PFs by disrupting the 
interaction between oocytes and somatic cells or granulosa 
cells, and/or by disrupting syncytial breakdown in folliculo-
genesis.
Folliculogenesis is under the control of molecular inter-
actions between germ cells and somatic cells, and is thought 
to involve several genes, e.g. Figα, Wnt4, Kit, KL, Cx43, 
MIS, GDF9, and FecX (Epifano and Dean, 2002). Double 
mutant Gdf9+/– and Bmp15–/– mice show PFs in their ova-
ries without DES treatment (Yan et al., 2001). The expres-
sion of GDF-9 and BMP-15 is localized in oocytes (McGrath 
et al., 1995; Dube et al., 1998), and that of inhibin-α and MIS 
in granulosa cells (Meunier et al., 1988; Ikeda et al., 2002). 
In the present study, neonatal DES exposure did not alter 
the expression of these genes in C57BL/6J, ERβ wild-type, 
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or βERKO mice; therefore, further studies are needed to 
clarify the genes related to PF induction by neonatal DES 
exposure.
Kipp et al. (2007) reported that neonatal DES or estrogen 
treatment decreased activin β-subunit mRNA and protein 
levels, with a reduction in the number of small antral follicles 
and the induction of PFs on postnatal day 19. Moreover, 
mice overexpressing inhibin-α show PFs in their ovaries 
without DES treatment (McMulle et al., 2001). In our study, 
the expression of inhibin-α subunit mRNA in DES-treated 
C57BL/6J mice was significantly higher than in oil controls 
only at day 60. At day 5, inhibin-α subunit mRNA showed no 
significant change. Thus, the up-regulation of inhibin-α at 
day 60 may not be directly related to PF induction by DES. 
The balance of inhibin and activin expression in the ovary 
could be important in the induction of PFs, and this needs 
to be clarified in the near future.
MIS and SF-1 are detected in rat granulosa cells, and 
MIS is a target gene of SF-1 (Ikeda et al., 1994, 2002; Hanley 
et al., 2000). Both MIS and SF-1 are critical factors regulat-
ing early ovarian differentiation (Durlinger et al., 1999). There-
fore, we studied the effects of DES on expression of these 
genes; however, we detected no change in the expression 
of these genes.
In both wild-type and βERKO mice, DES treatment sig-
nificantly reduced the expression of P450SCC at day 10. 
The expression of P450SCC is localized in interstitial cells 
(Ikeda et al., 2001), and these cells contain ERα protein. 
Thus, DES possibly suppresses P450SCC mRNA expres-
sion via ERα. Since hypertrophy of the interstitium is not 
observed in neonatally DES-treated αERKO mice (Couse et 
al., 2001), ERα may mediate the effects of DES on intersti-
tial cells.
In conclusion, neonatal DES treatment induces PFs 
through ERβ but not ERα, while DES acts on ovarian inter-
stitial cells through ERα. Further studies are essential to 
clarify the molecular mechanisms involved in the induction 
of PFs.
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